MBX Biosciences (MBX) Cash from Financing Activities (2023 - 2026)

MBX Biosciences has reported Cash from Financing Activities for 4 years, with the latest figure at $87.4 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 2185775.0% year-over-year to $87.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $277.0 million (up 18.42% YoY) and the FY2025 annual result came in at $189.6 million, down 19.01% from the prior year.
• Cash from Financing Activities grew to $87.4 million in Q1 2026 per MBX's latest filing, from $438000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $235.8 million in Q3 2024 and troughed at -$1.8 million in Q2 2024.
• A 4-year average of $51.1 million and a median of $310500.0 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities plunged 794.74% in 2024, then jumped 2185775.0% in 2026.
• Over 4 years, Cash from Financing Activities stood at $19000.0 in 2023, then slumped by 794.74% to -$132000.0 in 2024, then soared by 431.82% to $438000.0 in 2025, then surged by 19862.33% to $87.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $87.4 million, $438000.0, and $187.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.